NYSE · AMGN
Healthcare · Drug Manufacturers - General
$437.23
Down-$6.89 (-1.55%)
Updated Sep 8, 2026, 7:52 AM
SID Score
7.2/10
Composite research score
Smart Money
50/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AMGN closed at $437.23 after 20 trading sessions, up 4.80% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $437.03 | $441.85 | $435.00 | $437.23 | 1.66M |
| Sep 3, 2026 | $445.67 | $445.815 | $438.0801 | $444.12 | 1.84M |
| Sep 2, 2026 | $440.65 | $445.57 | $435.00 | $442.84 | 2.29M |
| Sep 1, 2026 | $435.301 | $438.65 | $431.00 | $438.12 | 2.36M |
| Aug 31, 2026 | $428.59 | $431.85 | $426.00 | $429.88 | 2.34M |
| Aug 28, 2026 | $437.89 | $437.89 | $430.72 | $432.42 | 1.74M |
| Aug 27, 2026 | $433.08 | $442.13 | $431.01 | $436.99 | 1.76M |
| Aug 26, 2026 | $441.00 | $442.885 | $438.24 | $440.34 | 2.29M |
| Aug 25, 2026 | $443.26 | $447.03 | $441.26 | $442.24 | 2.1M |
| Aug 24, 2026 | $440.31 | $445.87 | $435.51 | $443.84 | 2.46M |
| Aug 21, 2026 | $431.72 | $440.51 | $429.38 | $439.33 | 2.11M |
| Aug 20, 2026 | $435.78 | $441.34 | $431.07 | $433.73 | 2.91M |
| Aug 19, 2026 | $430.24 | $443.20 | $429.38 | $442.36 | 2.54M |
| Aug 18, 2026 | $421.64 | $427.39 | $420.72 | $425.28 | 2.59M |
| Aug 17, 2026 | $412.98 | $419.60 | $410.40 | $419.38 | 2.88M |
| Aug 14, 2026 | $413.76 | $416.03 | $410.50 | $415.21 | 2.04M |
| Aug 13, 2026 | $419.92 | $420.26 | $415.78 | $417.84 | 2.78M |
| Aug 12, 2026 | $413.31 | $418.1927 | $409.0001 | $416.18 | 2.07M |
| Aug 11, 2026 | $415.52 | $421.79 | $412.20 | $414.30 | 2.03M |
| Aug 10, 2026 | $408.46 | $417.36 | $406.42 | $417.20 | 1.96M |
The latest Smart Investors Daily articles mentioning AMGN.
AMGN research
Company profile and research snapshot.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 4, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 20, 2026 | Piper Sandler | Overweight | — |
| Aug 19, 2026 | Argus Research | Buy | — |
| Aug 18, 2026 | Mizuho | Neutral | — |
| Aug 18, 2026 | Cantor Fitzgerald | Neutral | — |
Generated Sep 7, 2026, 9:03 PM
Amgen shares declined 1.55% today following news that Novartis' pelacarsen, a competitive cardiovascular therapy, failed to meet its Phase III study endpoints. While Amgen is not the developer of pelacarsen, the failure of a late-stage rival drug in the cardiovascular space has created broader sector headwinds affecting biotech valuations.
Bottom line: Amgen's 1.55% decline appears driven by sector-wide biotech sentiment rather than company-specific negative news. While the pelacarsen failure highlights execution risks in cardiovascular therapy development, Amgen's scale, pipeline diversity, and established franchise portfolio position it to weather competitive headwinds and capitalize on long-term growth opportunities.
Yahoo · Sep 4, 2026
Amgen Inc. (NASDAQ:AMGN) reported that Repatha reduced the risk of all-cause mortality by 20% in a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial. The study enrolled more than 12,000 high-risk adults without a previous heart attack or stroke and followed them for a median of 4.6 years. The mortality reduction began to appear […]
Benzinga · Sep 4, 2026
Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $400 to $435.
Yahoo · Sep 3, 2026
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo · Sep 2, 2026
Amgen stock has logged a strong 5 year run, yet current valuation checks send mixed signals as the intrinsic value estimate suggests a discount while market based multiples look closer to fair. Over 5 years, Amgen has returned 134.2%, which means anyone looking at the stock today is weighing fresh gains against the chance that the easy part of the move is already behind it. New clinical data around Repatha and Tezspire can support expectations for future cash flows, while ongoing trial and...
Interpretive context generated from the platform’s current data sources.
Amgen Inc. shares closed at $437.23, reflecting a single-session decline of 2.50% per SID market data. Despite the daily pullback, the stock has demonstrated sustained upward momentum across multiple timeframes, gaining 8.0% over the past month, 25.07% over three months, and 36.11% over the trailing twelve-month period. The stock trades well above both its 50-day moving average of $397.06 and its 200-day moving average of $365.08, indicating a firmly bullish technical posture according to SID market data. The 14-day relative strength index registers at 61.6, positioning the stock in neutral-to-bullish territory without reaching overbought conditions. Amgen's beta of 0.472 underscores its defensive characteristics relative to the broader market. Average daily trading volume stands at approximately 2.89 million shares, supporting adequate liquidity. The company's market capitalization currently sits at approximately $209.2 billion, solidifying its position among the largest biotechnology firms globally.
Amgen Inc. trades at a price-to-earnings ratio of 27.13, which represents a premium relative to the broader healthcare sector's historical averages, per SID market data. The company's PEG ratio stands at 2.72, suggesting that the current earnings multiple exceeds the pace of anticipated earnings growth. The price-to-book ratio of 24.16 reflects Amgen's asset-light, intellectual-property-driven business model typical of large-cap biotechnology companies, according to SEC filings. Amgen offers a dividend yield of approximately 2.49%, providing an income component that remains attractive within the healthcare sector. The $209.2 billion market capitalization positions Amgen as a mega-cap biopharmaceutical company. The elevated valuation multiples may reflect investor confidence in the company's pipeline, including its obesity drug candidate MariTide. Investors weighing Amgen's current valuation should consider both the defensive beta profile and the premium embedded in forward growth expectations relative to current earnings delivery.
Amgen Inc. registers an overall smart money score of 50 out of 100 with a neutral signal, per SID market data. The institutional component scores a perfect 25 out of 25, reflecting strong and sustained positioning by major asset managers, according to 13F institutional filings. In contrast, the insider trading component scores 8.6 out of 25, with 15 insider transactions recorded over the past 90 days — comprising 9 purchases and 6 sales, according to SEC Form 4 filings. The net buying bias among insiders suggests a modestly constructive internal view of the company's trajectory. The dark pool activity score of 9.7 out of 25 indicates moderate off-exchange institutional interest without signaling aggressive accumulation. Congressional trading activity scores 6.8 out of 25, reflecting limited notable legislative trading. The divergence between the perfect institutional score and the below-average insider and dark pool readings creates a mixed composite picture, with large institutional holders maintaining conviction while other smart money indicators remain subdued.
Amgen Inc. has delivered consecutive earnings beats across its three most recently reported quarters, according to company earnings reports. In the most recent quarter, the company posted earnings per share of $6.29 against a consensus estimate of $5.60, representing a positive surprise of $0.69 or approximately 12.3%. The prior quarter produced EPS of $5.15 versus the $4.76 estimate, a $0.39 upside surprise, while the quarter before that delivered $5.29 against a $4.75 estimate, beating by $0.54. This pattern of consistent outperformance indicates disciplined cost management and stronger-than-expected revenue execution. Looking ahead, the next reporting date is scheduled for approximately early 2026, with analysts projecting earnings of $4.81 per share per analyst estimates. The sequential decline in the forward estimate relative to recent actuals likely reflects typical seasonal patterns in the company's product portfolio. Investors will monitor whether Amgen can sustain its earnings beat streak.
Wall Street analyst sentiment on Amgen Inc. reflects a balanced outlook, with recent coverage actions largely reiterating existing positions rather than signaling directional shifts, per Wall Street analyst reports. On September 4, 2026, Wells Fargo maintained its Equal-Weight rating, while Piper Sandler reiterated an Overweight rating on August 20. Argus Research reaffirmed a Buy rating on August 19, representing the most bullish stance among recent coverage updates. Both Mizuho and Cantor Fitzgerald maintained Neutral ratings on August 18, according to SID consensus data. The distribution shows two firms at Neutral or Equal-Weight, one at Overweight, and one at Buy, indicating a moderately constructive but not overwhelmingly bullish consensus. Notably, no analyst among recent coverage actions issued a downgrade or shifted to a negative stance, despite the stock's 36.11% twelve-month appreciation. The absence of rating changes suggests analysts view the current price as fairly reflecting near-term fundamentals while awaiting additional catalysts for conviction shifts.
The latest Smart Investors Daily articles mentioning AMGN.
